Table 2.
Prevalence of Oncogenic Drivers by Age
| <=50 years old n = 129 (%) | >50 years old n = 1923 (%) | P-value | |
|---|---|---|---|
| Clinically significant alteration | 78 (60.5) | 1018 (52.9) | 0.097 |
| KRAS | 37 (28.7) | 620 (32.2) | 0.402 |
| EGFR | 13 (10.1) | 168 (8.7) | 0.603 |
| BRAF | 4 (3.1) | 68 (3.5) | 0.795 |
| MET exon 14 skipping | - | 53 (2.8) | 0.076 |
| MET amplification | 2 (1.6) | 24 (1.2) | 0.677 |
| HER2 | 3 (2.3) | 32 (1.7) | 0.480 |
| Fusions (ALK/ROS1/RET/FGFR) | 19 (14.7) | 57 (3) | <0.001 |